Aytu BioScience, Inc. (OTC: AYTU) is a commercial-stage specialty healthcare company that focuses on urological and related conditions. The company’s products includes FDA-approved ProstaScint® (capromab pendetide), a radio-labeled monoclonal antibody that targets Prostate Specific Membrane Antigen (PSMA), a protein highly expressed by prostate cancer; as well as Primsol® (trimethoprim oral solution), the only FDA-approved oral solution of trimethoprim, the standard therapy for urinary tract infections.  Aytu’s seeks to continue building its portfolio of revenue-generating urology products and late-stage development assets. For more information, visit the company’s website at www.aytubio.com